Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study

Atherosclerosis

Volumn 246, Issue , 2016, Pages 309-317

  Lisowska, Anna ^a   Knapp, Małgorzata ^a   Tycińska, Agnieszka ^a   Motybel, Elzbieta ^a   Kamiński, Karol ^a   Świecki, Przemysław ^a   Musiał, Włodzimierz J ^a   Dymicka Piekarska, Violetta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Acute coronary syndromes; Galectin 3; Intima media thickness; Stable coronary artery disease

Indexed keywords

GALECTIN 3; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMMON CAROTID ARTERY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; AGED; AREA UNDER THE CURVE; BLOOD; CAROTID ARTERY; CAROTID ARTERY DISEASE; CASE CONTROL STUDY; CORONARY ANGIOGRAPHY; DIAGNOSTIC IMAGING; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; UPREGULATION;

AGED; AREA UNDER CURVE; BIOMARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GALECTIN 3; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; UP-REGULATION;

EID: 84956611164     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.022     Document Type: Article

References (26)

1. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 2009, 11:811-817.
2. Weir R.A., Petrie C.J., Murphy C.A., et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ. Heart Fail. 2013, 6(3):492-498.
3. Ho J.E., Liu C., Lyass A., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012, 60(14):1249-1256.
4. Felker G.M., Fiuzat M., Shaw L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ. Heart Fail. 2012, 5:72-78.
5. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 2011, 43(1):60-68.
6. Arar C., Gaudin J.C., Capron L., Legrand A. Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. FEBS Lett. 1998, 3;430(3):307-311.
7. Iacobini C., Menini S., Ricci C., et al. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler. Thromb. Vasc. Biol. 2009, 29(6):831-836.
8. Tsai T.H., Sung P.H., Chang L.T., et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J. Atheroscler. Thromb. 2012, 19(12):1073-1082.
9. Gullestad L., Ueland T., Kjekshus J., et al. The predictive value of galectin-3 for mortality and cardiovascular events in the controlled rosuvastatin multinational trial in heart failure (CORONA). Am. Heart J. 2012, 164(6):878-883.
10. Falcone C., Lucibello S., Mazzucchelli I., et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int. J. Immunopathol. Pharmacol. 2011, 24(4):905-913.
11. Menini S., Iacobini C., Ricci C., et al. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res. 2013, 100(3):472-480.
12. MacKinnon A.C., Liu X., Hadoke P.W., Miller M.R., Newby D.E., Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein e-deficient mice. Glycobiology 2013, 23(6):654-663.
13. Lisowska A., Musiał W.J., Prokop J. Clinical implications of ultrasonographic assessment of intima-media thickness in peripheral arteries. Pol. Przeglad Kardiologiczny 2003, 4:451-456.
14. Touboul P.J., Hennerici M.G., Meairs S., et al. Mannheim intima-media thickness consensus. Cerebrovasc. Dis. 2004, 18:346-349.
15. Hunt K.J., Sharrett A.R., Chambless L.E., Folsom A.R., Evans G.W., Heiss G. Acoustic shadowing on B-mode ultrasound of the carotid artery predicts CHD. Ultrasound Med. Biol. 2001, 27:357-365.
16. Gopal D.M., Kommineni M., Ayalon N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J. Am. Heart Assoc. 2012, 1(5):e000760.
17. Jin Q.H., Lou Y.F., Li T.L., Chen H.H., Liu Q., He X.J. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin. Med. J. Engl. 2013, 126(11):2109-2115.
18. Ozturk D.1, Celik O., Satilmis S., et al. Association between serum galectin-3 levels and coronary atherosclerosis and plaque burden/structure in patients with type 2 diabetes mellitus. Coron. Artery Dis. 2015, 26(5):396-401.
19. Lee Y.J., Koh Y.S., Park H.E., et al. Spatial and temporal expression, and statin responsiveness of galectin-1 and galectin-3 in murine atherosclerosis. Korean Circ. J. 2013, 43(4):223-230.
20. Gopal D.M., Kommineni M., Ayalon N., et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J. Am. Heart Assoc. 2012, 1(5):e000760.
21. Maiolino G., Rossitto G., Pedon L., et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2015, 35(3):725-732.
22. Jagodzinski A., Havulinna A.S., Appelbaum S., et al. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Int. J. Cardiol. 2015, 192:33-39.
23. George M., Shanmugam E., Srivatsan V., et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study. Ther. Adv. Cardiovasc Dis. 2015, 9(5):275-284.
24. Grandin E.W., Jarolim P., Murphy S.A., et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin. Chem. 2012, 58(1):267-273.
25. Hashmi S., Al-Salam S. Galectin-3 is expressed in the myocardium very early post-myocardial infarction. Cardiovasc Pathol. 2015, 24(4):213-223.
26. Kruk M., Menon V., Kadziela J., et al. Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the occluded artery trial (OAT) biomarker ancillary study. BMC Cardiovasc Disord. 2013, 13:91.